DWTX 8-K: Press Release Furnished on Second Quarter 2025 Results

Rhea-AI Filing Summary

Dogwood Therapeutics, Inc. furnished a press release reporting its results of operations for the quarter ended June 30, 2025, which is included as Exhibit 99.1 and is incorporated by reference into Item 2.02 of this Current Report.

The Form notes the information is being furnished, not filed, so it is not subject to Section 18 liability and is not incorporated by reference into other filings. The registrant identifies as an emerging growth company and did not check the box indicating an election to forgo the extended transition period. The company’s common stock trades on the Nasdaq Capital Market under ticker DWTX. The report is signed by Angela Walsh, Chief Financial Officer, Corporate Secretary and Treasurer.

Positive

• Press release announcing Q2 2025 results was furnished and included as Exhibit 99.1, indicating timely disclosure of operating results to the market.
• Company ticker and listing disclosed: common stock trades on the Nasdaq Capital Market under DWTX, providing clear market identification.

Negative

• No financial figures or operational metrics are included in the body of this Form 8-K, so the filing alone does not allow assessment of performance.
• Information is furnished, not filed, which limits Section 18 liability and means the content is not automatically incorporated by reference into other filings.

Insights

Financial Analyst

TL;DR: This 8-K furnishes Q2 2025 results via an attached press release; no financial figures appear in the 8-K itself, so market impact depends on Exhibit 99.1.

The filing merely furnishes a press release announcing results for the quarter ended June 30, 2025, and explicitly states the information is furnished, not filed. Because this Form 8-K contains no financial metrics or operational detail, investors and analysts cannot assess performance from the filing alone. Material implications therefore hinge entirely on the content of Exhibit 99.1; until that exhibit is reviewed, valuation or guidance impacts cannot be determined from this 8-K.

Corporate Governance Expert

TL;DR: The disclosure is procedural: the company furnished a press release and preserved the reduced liability associated with furnishing rather than filing.

The registrant’s choice to furnish rather than file the press release limits Section 18 liability and prevents automatic incorporation into future filings. The form also indicates the company is an emerging growth company and did not elect to forgo the extended transition period for new accounting rules. These are routine governance and disclosure decisions with no standalone adverse governance signals in the text provided.

0001818844false00018188442025-08-132025-08-13

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

​

Date of Report (Date of earliest event reported):  August 13, 2025

​

DOGWOOD THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

​

​	​	​
Delaware	001-39811	85-4314201
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

​

​ ​	​
44 Milton Avenue Alpharetta, GA	30009
(Address of principal executive offices)	(Zip Code)

​

Registrant’s telephone number, including area code:  (866) 620-8655

​

(Former name or former address, if changed since last report): Not Applicable

​

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001	DWTX	Nasdaq Capital Market

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

​	​
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
​	​
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
​	​
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
​	​
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company        ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       ☐

​

​

​

​

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, Dogwood Therapeutics, Inc. (the “Company”) issued a press release announcing the results of operations for the second quarter ended June 30, 2025. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference into this Item 2.02.

The information provided pursuant to this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.

​

Item 9.01 Financial Statements and Exhibits.

​

(d)Exhibits.

​

​	​	​
Exhibit Number		Description
99.1	​	Press Release of the Company, dated August 13, 2025 (furnished herewith).
104	​	Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

​

​

​

2

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​	​
	DOGWOOD THERAPEUTICS, INC.
	By:	/s/ Angela Walsh
	Name:	Angela Walsh
​	Title:	Chief Financial Officer, Corporate Secretary and Treasurer
August 13, 2025	​	​

​

​

​

​

​

​

​

3

FAQ

What did Dogwood Therapeutics (DWTX) disclose in this Form 8-K?

The company furnished a press releaseJune 30, 2025, which is included as Exhibit 99.1 and incorporated by reference into Item 2.02.

Does this 8-K include financial results or metrics for Q2 2025?

No. The Form 8-K references a press release in Exhibit 99.1 but does not include any financial figures or detailed operational metrics in the filing itself.

Is the information in the 8-K considered filed with the SEC?

No. The Form states the information and Exhibit 99.1 are being furnished, not filed, so they are not subject to Section 18 liability and are not incorporated by reference into other filings.

What exchange and ticker does Dogwood Therapeutics use?

The registrant’s common stock trades on the Nasdaq Capital Market under the ticker DWTX.

Is Dogwood Therapeutics an emerging growth company?

Yes. The filing indicates the registrant is an emerging growth company and did not check the box electing to forgo the extended transition period for new accounting standards.

Who signed the Form 8-K for Dogwood Therapeutics?

The report is signed by Angela Walsh, Chief Financial Officer, Corporate Secretary and Treasurer.